NADH and Methylene Blue Together: The Stack Nobody Has Ever Tested

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Direct answer: No study — human, animal, or laboratory combination experiment — has ever tested supplemental NADH taken together with methylene blue. (Evidence: absent.) The chemistry connecting them is real and unusually direct: methylene blue is reduced by enzymes at the expense of NADH, and in cells it raises the NAD+/NADH ratio by oxidising NADH, not by preserving it. (Evidence: established in vitro and in cells; untested in supplemented humans.) For a healthy adult, the pair is best described as mechanistically intelligible, evidentially untested, and largely redundant, with the risk concentrated entirely in methylene blue, a real drug with an FDA boxed warning. (Evidence: expert synthesis of the graded findings below.)

The pitch sounds perfect: NADH donates the electrons, methylene blue shuttles them. The biochemistry says something less convenient — methylene blue burns NADH, nobody has ever studied the pair in a person, and every serious risk sits on one side of the stack. This article grades what is actually known about the pair, about each half on its own, and about the safety rules that are not optional if methylene blue is involved at all.

Has anyone actually studied NADH and methylene blue together?

No. A targeted search of the published literature found no human trial of the two taken together, no animal study administering both, no laboratory study designed to test the combination, no case report of anyone taking the pair, and no clinician protocol for combining NADH specifically with methylene blue. (Evidence: absent.)

That surprises people, because “methylene blue plus NAD” stacks are marketed everywhere. Look at the labels, though, and the “NAD” is almost never NADH:

• One widely shared protocol pairs methylene blue (0.5–1 mg/kg) with NMN 250–500 mg — a precursor, not NADH.
• A combination capsule called NMN Blue contains NMN 500 mg plus methylene blue 10 mg.
• A “triple power” tablet combines methylene blue 5 mg with NAD+ 20 mg — the oxidised form, the chemical opposite of NADH.

The synergy percentages in the marketing for these stacks (“60% greater reduction in oxidative stress,” “35% more mitochondrial density”) match no primary study we could find. (Evidence: absent.) And the rationale for a precursor stack — enlarge the NAD pool, then improve how it recycles — does not transfer to NADH, which pushes the pool in the opposite, reduced direction. NAD+, NADH, NMN and NR are four different molecules, and stack marketing uses them as if they were interchangeable. They are not.

What does methylene blue actually do to NADH?

This part of the story is genuinely established biochemistry. Methylene blue sits, electrically, between NADH and cytochrome c. Enzymes powered by NADH — including Complex I itself and enzymes literally named for this reaction, the diaphorases — pass electrons from NADH to methylene blue, converting it to its colourless form, leucomethylene blue. Leucomethylene blue then hands those electrons to cytochrome c, which feeds Complex IV, the chain's final step. In laboratory work, that detour lets electrons from NADH reach the end of the chain even when Complexes I and III are blocked, raising oxygen consumption and protecting cells in models of mitochondrial damage. (Evidence: established in vitro and in animal models — Wen et al., Journal of Biological Chemistry, 2011.)

Three consequences follow, and each one complicates the sales pitch.

First, methylene blue consumes NADH. In solution, methylene blue directly oxidises NADH to NAD+, a reaction demonstrated in 1993 and re-measured with modern spectroscopy in 2025. In human fibroblasts, methylene blue raised the NAD/NADH ratio by 63% within 15 minutes — not by making new NAD, but by burning NADH — before the effect faded by 24 hours. (Evidence: established in vitro; preliminary in cells — Helander 1993; Pominova 2025; Atamna 2015.) Clinicians have used exactly this property in hospital care: methylene blue is an accepted treatment for ifosfamide-induced encephalopathy partly because it disposes of the excess NADH that drug creates. Methylene blue is not a way to boost your NADH. It is a way to spend it.

Second, the bypass is not free. Complexes I and III are proton pumps; they are how the chain converts electron flow into ATP. Routing NADH's electrons straight to cytochrome c skips both pumps, so each NADH yields less ATP even as oxygen consumption rises. In a chain that is blocked, that trade can be worth it. In a healthy chain, the bypass can be a short-circuit: more oxygen burned, more heat, not more energy. (Evidence: established bioenergetics.)

Third, the same chemistry has a shadow side. When leucomethylene blue is re-oxidised by oxygen instead of cytochrome c, the product is hydrogen peroxide. Methylene blue has been shown since 1998 to catalyse exactly that reaction using NADH, NADPH and glutathione as fuel, and enzyme researchers coined the term “subversive substrate” for how it turns antioxidant enzymes into peroxide producers. Most strikingly, in a 2014 cell-free experiment, methylene blue damaged DNA — including at a hotspot in the p53 gene — only when NADH and copper or iron were also present; remove the NADH or the metal and the damage disappeared. That is a test tube, not a person, and it does not prove the supplements harm anyone. But it is the single most relevant safety experiment ever run on this exact pair, and it points the wrong way for the idea that more NADH with methylene blue is automatically better. (Evidence: established in vitro; human relevance absent.)

Which route methylene blue takes in your body — productive (cytochrome c), wasteful (oxygen, peroxide), or worse (metals, radical damage) — depends on dose, on whether your electron transport chain is actually impaired, and on factors no supplement user can measure. Extra NADH feeds all three routes, not just the good one.

What about NADH on its own?

NADH's first problem is that it barely survives being a supplement. It is degraded by acid, oxygen, heat and light, so legitimate products are stabilisation technologies — the patented ENADA form used in the early trials, sublingual lozenges such as ENADAlert, or PANMOL, NADH micro-encapsulated in fat and chlorophyll. Whether intact oral NADH is even absorbed, and raises NAD levels in human tissue, is contested: a pharmacology review concludes plasma and tissue NAD+ do not rise significantly after oral NADH, and no modern human pharmacokinetic study of a commercial product settles it. Any benefit may come from breakdown products rather than NADH itself. (Evidence: contested.)

Its trial record is thin, old and small:

• Chronic fatigue, 1999: in a double-blind crossover pilot of 26 patients, 31% responded favourably to 10 mg/day of stabilised NADH versus 8% on placebo. The authors called for larger trials; for NADH alone, they never came. (Evidence: preliminary.)
• Jet lag, 2002: a single 20 mg sublingual dose after an overnight flight improved four cognitive measures and reduced sleepiness in 35 healthy adults, in one small study. (Evidence: preliminary.)
• Parkinson's, 1993: an open-label, uncontrolled series of 885 patients reported improvement — but with no placebo group and the investigator grading his own patients on his own scale, and it has never been replicated in a blinded trial. NADH is not a Parkinson's treatment in any guideline. (Evidence: contested.)
• Dementia, 2000: an independent attempt to reproduce earlier positive claims found no cognitive effect at all. (Evidence: contested, replication negative.)
• Athletes: a double-blind trial at 30 mg/day found no effect on aerobic capacity, lactate, reaction time or fatigue. (Evidence: preliminary, null.)
• The largest modern trial, 207 people with ME/CFS in 2021, tested NADH 20 mg/day combined with CoQ10 200 mg — the one partner with which NADH has actually been trialled — and its benefits were largely within-group changes that cannot be credited to NADH specifically. (Evidence: preliminary, for the pair.)

Safety is the kindest thing in NADH's file: no severe adverse effects in its small trials, though reference summaries report jitteriness, anxiety and insomnia at doses of 10 mg/day and up, and there are no long-term or pregnancy safety data. (Evidence: preliminary.) Note also what NADH is not: it is not a precursor like NR or NMN, which reliably raise blood NAD+ in trials by rebuilding the molecule inside the cell. NADH is the finished, reduced product, delivered across four barriers it is poorly built to cross.

And methylene blue on its own?

Methylene blue is a drug with a narrow official life. The FDA approves it only as an intravenous treatment for acquired methemoglobinemia, a blood disorder, at 1 mg/kg. There is no FDA-approved oral dose, and no controlled trial of daily oral methylene blue for energy or cognition in healthy adults — the frequently cited human memory study used a single 280 mg dose, roughly 28 times a typical 10 mg supplement serving. (Evidence: established, from the FDA label.)

Its dose behaviour is hormetic, and this is established: at low doses it cycles electrons and can act as an antioxidant; at high doses it inhibits respiration, generates oxidants, and causes the very methemoglobinemia it treats at low dose. Cumulative intravenous doses above about 7 mg/kg are a documented harm landmark. Where the flip point sits for oral use in milligrams, nobody has established. (Evidence: established as a principle; the oral threshold is absent.)

What are the non-negotiables if someone takes methylene blue at all?

Everything serious on this list belongs to methylene blue, and none of it is optional:

1. Medication check first — this is the big one. Methylene blue is a potent inhibitor of monoamine oxidase A, and its FDA label carries a boxed warning: serious or fatal serotonin syndrome when combined with serotonergic drugs and opioids — SSRIs, SNRIs, MAO inhibitors, tramadol and similar painkillers, dextromethorphan (in common cough medicines), and more. Most published cases involved hospital IV doses, but no safe low oral dose alongside these medicines has ever been established. The label's instruction is “avoid.” (Evidence: established — FDA label.)
2. G6PD testing. Methylene blue is contraindicated in G6PD deficiency: it can trigger severe haemolytic anaemia, and because red blood cells need G6PD's output to activate the drug, it won't even work properly. Test; do not guess. (Evidence: established — FDA label.)
3. No use in pregnancy. Older labels classified it Category X after a link between exposure during amniocentesis and intestinal birth defects; the current label restricts it to cases where benefit justifies risk. For elective wellness use, that is a no. (Evidence: established — FDA labels.)
4. Pharmaceutical grade only. USP/pharmaceutical-grade methylene blue with a batch certificate of analysis. Industrial, laboratory and aquarium grades are not made for humans and may carry heavy-metal and dye-impurity contamination — a warning repeated across the clinical literature. (Evidence: established as a quality risk.)
5. Dose discipline. Lowest dose, morning, no escalation logic. The hormetic flip, the MAO-A effect and the methemoglobinemia risk are all dose phenomena, and there are no long-term daily-use safety data to hide behind. (Evidence: established.)
6. Do not dissolve the two together. Methylene blue oxidises NADH on contact in solution — that is the 1993 chemistry above — so a combined drink or troche is the worst-supported format imaginable. No tested sequencing protocol for the pair exists at all; anyone publishing a precise schedule for it is inventing one. (Evidence: established chemistry; scheduling guidance absent.)

If you are on an antidepressant or a serotonergic painkiller, the honest answer is simpler: this stack is not for you, at any dose anyone can currently defend.

The bottom line

NADH plus methylene blue is a stack built on a true sentence — methylene blue takes electrons from NADH — and a false implication: that supplying more of both means more energy. The same literature shows methylene blue spending NADH, sometimes productively, sometimes as hydrogen peroxide; shows the bypass costing ATP efficiency in a healthy chain; and contains, after a hard search, zero studies of the two taken together by anyone, anywhere. If the mechanism in the marketing appeals to you, methylene blue is the agent doing the work, and it demands drug-level respect: medication screening, G6PD testing, pharmaceutical grade, low dose. NADH adds an unproven, probably redundant input to that system — the one partner NADH has actually been trialled with is CoQ10, not methylene blue. Rational in a narrow, unverifiable scenario; redundant for most healthy people; and risky exactly where its promoters are most casual.

Where the evidence stands

• Absent: No human trial, animal study, laboratory combination experiment, case report or dosing protocol has ever tested supplemental NADH taken together with methylene blue.
• Established: Methylene blue is reduced at the expense of NADH and directly oxidises NADH to NAD+; in human fibroblasts it raised the NAD+/NADH ratio by 63% within 15 minutes by burning NADH, and hospitals have used it to dispose of excess NADH (Helander 1993; Atamna 2015; Küpfer 1996).
• Established: The methylene blue bypass routes NADH's electrons straight to cytochrome c, skipping the proton-pumping Complexes I and III — so each NADH yields less ATP even as oxygen consumption rises (Wen 2011).
• Established (in vitro): Methylene blue catalyses hydrogen peroxide production from NADH, NADPH and glutathione, and methylene blue plus NADH with copper or iron caused oxidative DNA damage in a cell-free system; human relevance is untested (Biaglow 1998; Buchholz 2008; Hiraku 2014).
• Contested: Whether intact oral NADH is absorbed and raises tissue NAD+ is unresolved, and its trial record is small, old and mixed; the largest modern NADH trial paired it with CoQ10, not methylene blue (Castro-Marrero 2021).
• Established: Methylene blue's only FDA approval is intravenous treatment of acquired methemoglobinemia at 1 mg/kg; its label carries a boxed warning for serotonin syndrome (it is a potent MAO-A inhibitor) and a contraindication in G6PD deficiency. No oral dose is approved.